<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article>
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">The Journal Title</journal-id>
      <issn pub-type="epub">0000-000X</issn>
      <publisher>
        <publisher-name>The Publisher Name</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.1000/123456</article-id>
      <article-categories>
        <subj-group>
          <subject>Sample Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Sample Article Title</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Eve</surname>
            <given-names>Martin Paul</given-names>
          </name>
          <xref ref-type="aff" rid="lincoln"/>
        </contrib>
        <aff id="lincoln">
          <institution>University of Lincoln</institution>
        </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <year>2013</year>
      </pub-date>
      <volume>1</volume>
      <issue>1</issue>
      <fpage>1</fpage>
      <lpage>2</lpage>
      <permissions>
        <copyright-statement>Copyright &#169; 2014, Martin Paul Eve</copyright-statement>
        <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The citation of this article must include: the name(s) of the authors, the name of the journal, the full URL of the article (in a hyperlinked format if distributed online) and the DOI number of the article.</license-p>
        </license>
      </permissions>
      <self-uri>https://www.martineve.com/</self-uri>
      <abstract>
        <p>This is a sample abstract that forms part of the metadataSample.xml file in meTypeset.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Prokinetic Drug Utility in the Treatment of Gastro-Esophageal Reflux Esophagitis:</title>
      <sec>
        <title>A Systematic Review of Randomized Controlled Trials</title>
      </sec>
      <sec>
        <title>Short title: Prokinetic for the Treatment of Esophagitis</title>
        <sec>
          <title>Abstract</title>
          <p><bold>Background knowledge.</bold> Esophagitis caused by gastroesophageal reflux disease (<xref rid="TO_LINK" ref-type="bibr" id="IDdb666d11-9abe-437f-810c-2a69b4864d21">GERD</xref>) results in appreciable morbidity and economic burden. No systematic review has addressed the effectiveness of prokinetic drugs in the treatment of GERD esophagitis in adults.</p>
          <p><bold>Objective.</bold> To determine the utility of prokinetic drugs in improving symptoms and endoscopic lesions in patients with GERD esophagitis.</p>
          <p><bold>Methods.</bold> We included randomized controlled trials comparing prokinetic drugs with placebo. A systematic search included Cochrane Controlled Trial Register, MEDLINE, CINAHL, LILACS, EMBASE and manual search of books and articles&#8217; references and contact with pharmaceutical companies. Reviewers assessed methodological quality, and extracted data that was combined using a random effects model.</p>
          <p><bold>Results. </bold>Seventeen articles fulfilled eligibility criteria; 13 used prokinetic drugs alone, 4 tested prokinetic drugs as additional therapy in patients receiving histamine-2 receptor blockers. Seven studies evaluated clinical improvement only, 5 addressed endoscopic improvement only, and 5 reported both outcomes. Four studies failed to provide adequate data for pooling; three of the four reported results suggesting symptomatic benefit with prokinetic agents. Eight studies (<xref rid="TO_LINK" ref-type="bibr" id="IDfcd991a8-d12b-46ae-8ef8-69c6f7805956">347 patients</xref>) that provided the required data suggested a higher incidence of clinical improvement with prokinetic drugs versus placebo (RR 1.68, 95% CI 1.31-2.17, heterogeneity <italic>p</italic> = .39, I<xref ref-type="fn" rid="bibd2e66"/> 5.5%). Clinical improvement occurred in 47 out of 162 patients (<xref rid="TO_LINK" ref-type="bibr" id="ID2d6d9a37-e5d5-44f2-abb8-1644ff4804be">29%</xref>) of the control group; applying the RR of 1.68 and associated confidence interval suggests that absolute increases in patients improved might vary from 16% to 38% (<xref rid="TO_LINK" ref-type="bibr" id="ID4ed6b47c-aff0-493e-a6f0-cdff8c280e6d">number needed to treat approximately 3 to 6</xref>).  The funnel plot, however, suggests the possibility of publication bias.</p>
          <p>Ten studies (<xref rid="TO_LINK" ref-type="bibr" id="ID55541004-4c79-479d-bae4-3eae4f8fa849">859 patients</xref>) suggested a higher likelihood of endoscopic improvement or healing esophagitis with prokinetic drugs (<xref rid="TO_LINK" ref-type="bibr" id="IDd8f0a9d3-e0a9-4301-a938-3ca565c14026">RR 1.35, 95% CI, 1.05-1.72</xref>) but with significant heterogeneity (heterogeneity <italic>p</italic> = .006, I<xref ref-type="fn" rid="bibd2e75"/> 60.7%) that we couldn&#8217;t explain with <italic>a priori</italic> hypothesis.  </p>
          <p><bold>Conclusions.</bold> Randomized Controlled Trials provide moderate quality evidence that prokinetic drugs improve symptoms in patients with reflux esophagitis and very low quality evidence that they impact on endoscopic healing.</p>
        </sec>
        <sec>
          <title>Introduction</title>
          <p>Esophagitis is a frequent complication of gastroesophageal reflux disease (<xref rid="TO_LINK" ref-type="bibr" id="ID9e90f9c9-c521-4d8b-8985-ba385d2aeacb">GERD</xref>). The diversity of clinical manifestations and the lack of standardized diagnostic criteria across studies creates difficulties in estimating its prevalence. 1;2. Pathophysiologic mechanisms include anatomic and functional changes of the gastroesophageal junction (hiatal hernia, decrease of the inferior esophageal sphincter tone and esophageal clearance)<xref ref-type="fn" rid="bibd2e95"/>. Definitive diagnosis of esophagitis requires endoscopy and biopsy<xref ref-type="fn" rid="bibd2e99"/>.</p>
          <p>Chronic esophagitis complications include bleeding, esophageal stenosis, Barrett metaplasia and adenocarcinoma. The goal of medical treatment is to decrease symptoms and complications by the suppression of gastric acid secretion and by ameliorating motor dysfunction. Therapeutic options include proton pump inhibitors (<xref rid="TO_LINK" ref-type="bibr" id="ID2495581d-aa12-47bb-a5ae-494547657f0a">PPI</xref>), histamine-2 receptor (H2) antagonists and prokinetic drugs.</p>
          <p>Prokinetic drugs have potential usefulness as adjunctive treatment of GERD by increasing lower esophageal sphincter pressure, enhancing gastric emptying, and improving peristalsis. A clinical practice guideline on GERD esophagitis <xref ref-type="fn" rid="bibd2e107"/> suggested the potential benefit of promotility agents, either as monotherapy or used in association with PPI. The authors emphazised the need for continued research into the role of these agents. </p>
          <p>Any further research or recommendations regarding prokinetic agents should, however, be based on a systematic summary of evidence to date.  While systematic reviews have examined the short-term impact of prokinetic agents <xref ref-type="fn" rid="bibd2e113"/> on gastroesophageal reflux symptoms in patients without endoscopically proven esophagitis, no systematic review has evaluated their effect on endoscopically proven esophagitis in adults. We therefore undertook a systematic review and meta-analysis to evaluate the real effectiveness of prokinetic drugs in patients with proven GERD esophagitis.</p>
        </sec>
      </sec>
      <sec>
        <title>Materials and Methods</title>
      </sec>
      <sec>
        <title>Eligibility Criteria</title>
        <p>We included all published and unpublished parallel group randomized or quasi-randomized controlled trials published in Spanish, English, French, German, Italian or Portuguese that met the following criteria: <italic>Patients:</italic> adults older than 15 years with endoscopic diagnosis of reflux esophagitis (<xref rid="TO_LINK" ref-type="bibr" id="IDb9ae2968-668b-4e59-8fe2-f08f8ccb9d4b">with or without histology</xref>). <italic>Intervention:</italic> use of oral prokinetic agents (cisapride, mosapride, tegaserod, metoclopramide, domperidone, bethanechol, levosulpiride, cinitrapide, clebopride) compared with placebo. If patients received antisecretory agents (<xref rid="TO_LINK" ref-type="bibr" id="IDa5ef61e9-d815-47e8-8439-86288be6b75b">PPI or H2 antagonists</xref>) studies were included only if patients in both treatment and control groups, received these agents according to the same protocol. <italic>Outcomes</italic>: any of symptomatic improvement (<xref rid="TO_LINK" ref-type="bibr" id="IDb354d2cd-473a-4ac3-93cb-6a07b177a5da">heartburn, regurgitation, dysphagia, retrosternal pain</xref>) or endoscopic findings.</p>
        <p>We excluded studies with: <italic>Patients:</italic> those with esophageal involvement of a systemic illness (<xref rid="TO_LINK" ref-type="bibr" id="ID6ee035db-63eb-4a09-a2aa-1e1ea9eb1967">scleroderma, dermatomyositis</xref>), dysphagia of neurologic cause, previous gastrectomy or antireflux surgery. <italic>Intervention:</italic> use of prokinetics after satisfactory treatment with PPI or for symptomatic relapse. <italic>Trial design</italic>: trials with scores of 3 or less in the Jadad scale modified by Schulz criteria (<xref rid="TO_LINK" ref-type="bibr" id="ID32e51ad0-a064-47e5-bdc7-702ae0f4c0f2">score 0 to 8</xref>)<xref ref-type="fn" rid="bibd2e147"/>.</p>
        <p>Titles and abstracts were independently reviewed by two of the authors (<xref rid="TO_LINK" ref-type="bibr" id="ID2a7c7b30-da2d-492d-a4f0-6a23aabbf4a2">MEM and FAS</xref>) to identify potentially eligible articles. We obtained full-text versions of potentially eligible articles, which the same two reviewers evaluated. In case of disagreement, one of three (<xref rid="TO_LINK" ref-type="bibr" id="IDd2444334-1b4a-4fc7-849f-5c7d2895d79c">MFK, GD and HNC</xref>) other reviewers made the eligibility decision.</p>
        <sec>
          <title>Search Strategy</title>
          <p>We searched relevant articles in the following electronic databases: LILACS (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDdd46a439-6ab3-4e00-bd5d-6feecde53606">1985-2003</xref>), MEDLINE (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDbd21fcc3-7947-4931-b2da-048afe432056">1966-2003</xref>), EMBASE (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID17654b6e-06c5-4089-a167-1b345c9262a7">1980-2003</xref>), CINHAL (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID6f1bfd14-ca52-4018-a53b-b6440c4f8a1a">1982-2004</xref>), COCHRANE Controlled Trial Register (<xref rid="TO_LINK" ref-type="bibr" id="ID317cdcbd-52af-43ae-98ce-71523c326769">Cochrane Library 2003</xref>). The terms used were prokinetic agents, generic and brandnames, combined with reflux esophagitis and therapeutic articles. We also hand-searched abstracts reported in the European Congress of Gastroenterology, United European Gastroenterology Week and in the American Congress of the American Gastroenterological Association. We reviewed the reference lists of included articles, other sources such as UptoDate (<xref rid="TO_LINK" ref-type="bibr" id="IDb68fcf85-6fa3-4e9e-8f99-65ac4c226fc8">2003 version 11.2</xref>) and relevant Gastroenterology, Pharmacology and Internal Medicine textbooks. We also contacted a local expert and five pharmaceutical companies (<xref rid="TO_LINK" ref-type="bibr" id="ID89b371a8-267b-4d42-8518-beaafd01235f">Beta, Roux Ocefa, Janssen-Cilag, Phoenix, and Cetus</xref>) to identify unpublished articles.</p>
        </sec>
        <sec>
          <title>Quality</title>
          <p>Two of the authors (<xref rid="TO_LINK" ref-type="bibr" id="ID488a22d2-3885-4794-ad59-cb03e5d21d61">MEM and FAS</xref>) independently evaluated concealment allocation, blinding and completeness of follow-up. The reviewers used Jadad scale modified by Schulz criteria to evaluate and classify the articles&#8217; quality.<xref ref-type="fn" rid="bibd2e165"/>
               </p>
        </sec>
        <sec>
          <title>Data abstraction</title>
          <p>Two of the authors (<xref rid="TO_LINK" ref-type="bibr" id="ID056a8c21-bed5-42fe-8135-5c494b91fbc0">MEM and FAS</xref>) independently abstracted the data in duplicate. Patients&#8217; characteristics, interventions (<xref rid="TO_LINK" ref-type="bibr" id="IDcd013dc4-3a64-4d06-bad7-e98ca38031e9">drugs used, dose, time of administration, co-interventions</xref>), outcome measures (symptomatic or endoscopic response, endoscopic healing and adverse events) were abstracted and disagreement was resolved through discussion. We made attempts to contact authors regarding confirmation or missing data; two authors answered our request.</p>
        </sec>
        <sec>
          <title>Quantitative Data Synthesis and Statistical Analysis</title>
          <p>We used weighted kappa to assess agreement between the reviewers on the selection of articles for inclusion. We calculated relative risk (RR) and absolute risk reduction (<xref rid="TO_LINK" ref-type="bibr" id="IDa8ae43c5-c151-4ac1-8106-0cc89e643679">ARR</xref>) with 95% confidence intervals (CI) for symptomatic and endoscopic response, and combined the RR from each study by means of a meta-analytic technique using a random effects model as described by DerSimonian and Laird <xref ref-type="fn" rid="bibd2e180"/>. RevMan 4.2 was used to analyze all data. </p>
          <p>The authors of trials used different scores to assess improvement (<xref rid="TO_LINK" ref-type="bibr" id="IDaf6838b0-6892-4bd2-b1d8-e46569a0aa48">0 to 100 symptom scale</xref>; <xref rid="TO_LINK" ref-type="bibr" id="ID3dff7dd1-01b5-4e14-82d1-d351d748b7ad">categorical scale from absent to disabling symptoms</xref>). We used the authors&#8217; own criteria in each trial to classify patients as improved or unimproved.  We considered outcomes of patients free of symptoms and patients with symptomatic improvement as equivalent and pooled each outcome of interest based on <italic>a priori</italic> expectation of a similar magnitude and direction of treatment effect. We classified &#8220;some improvement&#8221; with complete symptom resolution as a positive outcome and &#8220;no improvement&#8221; as a negative outcome.</p>
          <p>Heterogeneity of the studies was evaluated both by the Chi-squre test with a threshold <italic>p </italic>value of less than .05, and by I<xref ref-type="fn" rid="bibd2e194"/> statistic (considering important heterogeneity a proportion higher than 30%). For any outcome that crossed either threshold for heterogeneity, we explored sources of heterogeneity according to our <italic>a priori</italic> hypothesis, which included drugs used, use of additional agents, dosing, duration of treatment and methodological quality. Specifically, we compared the results of studies grouped by the following factors: 1- different drugs used (cisapride, metoclopramide, bethanechol, levosulpiride, domperidone); 2-use of antisecretory agents (<xref rid="TO_LINK" ref-type="bibr" id="ID1088818e-554a-480a-ac64-62534cf50211">yes or no</xref>); 3- dose of prokinetic drugs used per day (&lt; 40mg vs &#61619; 40mg of cisapride, &lt; 40mg vs &#61619; 40mg metoclopramide); 4- treatment duration (<xref rid="TO_LINK" ref-type="bibr" id="ID165827ff-6b17-4784-b302-8d8615413ba9">&#61603;8 weeks vs &#61502;8 weeks</xref>); 5- methodological qualtity (<xref rid="TO_LINK" ref-type="bibr" id="IDb84adbe7-5070-447d-9ab5-56d53a2320e3">Jadad score 4 vs &#61619;5</xref>).  We used log-transformed RR and its standard error calculated from 95% CI and Z value to obtain p-values for testing explanations of heterogeneity. </p>
          <p>All data were analyzed on an intention to treat principle. Publication bias was evaluated using funnel plots.</p>
        </sec>
        <sec>
          <title>Funding Source</title>
          <p>None</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>We identified 1,011 abstracts (<xref rid="TO_LINK" ref-type="bibr" id="ID03cee35f-2dc8-4fa2-8849-cab9017dfabc">Figure 1</xref>). Studies provided by pharmaceutical companies were of low methodological quality and thus ineligible (<xref rid="TO_LINK" ref-type="bibr" id="IDa14af423-2067-46b8-bcfa-499a0f2938ea">13 non-randomized controlled trials</xref>), or (<xref rid="TO_LINK" ref-type="bibr" id="IDa28dae91-3ab6-4a57-8380-e2c34ae65d41">in the case of 2 RCTs</xref>) reported neither symptoms nor endoscopic improvement. Seventeen RCTs enrolling 1,123 patients (602 in the intervention and 491 in the placebo group, table 1) all identified from electronic databases, proved eligible. <xref rid="ID2a7baa4d-f014-42e3-bd19-f3bbf1a1057c" ref-type="table">Table 2</xref> shows characteristics and methodological quality of the eligible trials. Eleven trials rated 4 using the Jadad scale modified by Schulz criteria and six rated 5 or more; 11 trials were sponsored by pharmaceutical industry. Five RCTs failed to provide sponsorship information, and one had no sponsor.</p>
          <p>Eleven trials evaluated the effect of cisapride. One trial evaluated 80mg/day dose, nine trials 40mg/day dose, two 30mg/day dose and only one 15mg/day dose. Metoclopramide was evaluated in 3 studies, one evaluated 30mg/day dose and two others 40mg/day dose. One study evaluated bethanechol. Two studies evaluated sulpiride and domperidone. Four trials compared the addition of a prokinetic drug versus placebo in patients already using an H-2 receptor blocker (<xref rid="TO_LINK" ref-type="bibr" id="ID1cc37796-88f7-4efd-9457-518e442f43d7">3 cimetidine and 1 ranitidine</xref>). No trial evaluated the addition of a prokinetic agent to a PPI.</p>
          <p><xref rid="ID9579e9b8-327b-49e3-bede-dbebd0022157" ref-type="table">Table 3</xref> and 4 show primary outcomes and adverse reactions.</p>
        </sec>
      </sec>
      <sec>
        <title>Studies that did not provide data for pooling </title>
        <p>Masci <italic>et al</italic> 
               <xref ref-type="fn" rid="bibd2e231"/> evaluated the presence and severity of reflux symptoms (dysphagia, regurgitation, heartburn, retrosternal pain, nausea) comparing levosulpiride, domperidone and placebo. They reported equal effectiveness of both drugs significantly reducing regurgitation, heartburn and overall dyspeptic symptoms (<xref rid="TO_LINK" ref-type="bibr" id="IDe41646fe-732f-471a-b9fb-e192c9a3e237">p &lt; 0.05 compared with control</xref>). Endoscopic features failed to reveal significant differences between groups.</p>
        <p>Trabucchi <italic>et al</italic> 
               <xref ref-type="fn" rid="bibd2e240"/> compared levosulpiride with placebo. They reported improvement in symptom score in most patients in treatment group. Endoscopic lesions disappeared in 20%, improved in 47% and failed to improve in 33% .  The authors did not provide data for the placebo arm.</p>
        <p>Finizia <italic>et al</italic> 
               <xref ref-type="fn" rid="bibd2e249"/> reported no significant difference on symptom score according to intensity, frequency and duration in the cisapride group compared to placebo.</p>
        <p>Pehlivanov <italic>et al</italic> 
               <xref ref-type="fn" rid="bibd2e258"/> found less heartburn episodes during daytime and less antacid tablets needed per patient in a week in the cisapride group versus placebo group, <italic>p </italic>value of .016 and .062, respectively. </p>
        <sec>
          <title>Clinical Improvement</title>
          <p>Eight studies (<xref rid="TO_LINK" ref-type="bibr" id="ID6b759fd2-3500-4730-b159-4fa32f8d2871">347 patients</xref>) evaluated clinical improvement. The pooled estimate showed a significant improvement with prokinetic drugs versus placebo (<xref rid="TO_LINK" ref-type="bibr" id="ID04a5fd92-c998-4178-84fb-c52118375210">RR 1.68, 95% CI, 1.31-2.17</xref>). Results were consistent across studies (<italic>p</italic> = .39, I<xref ref-type="fn" rid="bibd2e274"/> 5.5%). The absolute risk reduction was 27% (<xref rid="TO_LINK" ref-type="bibr" id="IDa2be85f3-9cb1-4102-8af2-2f9e49b80064">95% CI, 16-38</xref>) (<xref rid="TO_LINK" ref-type="bibr" id="ID300bc0cc-6aad-42e3-bf38-02a8eb2c4ba3">Table 3</xref>).  </p>
        </sec>
      </sec>
      <sec>
        <title>Endoscopic Improvement</title>
        <p>The pooled estimate of treatment effect on endoscopic healing or improvement from ten studies including 859 patients demonstrated a significant effect of prokinetic drug versus placebo (<xref rid="TO_LINK" ref-type="bibr" id="ID77d57dd7-4744-452d-9a25-8e9b46b6c135">RR 1.35, 95% CI 1.05-1.72</xref>); the risk difference was 20% (<xref rid="TO_LINK" ref-type="bibr" id="IDc05af224-5ac6-46b8-a64c-43370e905a03">CI 95% 6-34</xref>).  The results were, however, extremely variable from study to study (test for heterogeneity <italic>p </italic>= .006, I<xref ref-type="fn" rid="bibd2e287"/> 60.7%). We therefore explored the possible sources of heterogeneity according to our <italic>a priori</italic> hypothesis. The a priori hypotheses failed to explain the variability in study results. </p>
        <sec>
          <title>Adverse events</title>
          <p>Twelve trials reported adverse events. They showed a non significant increase on adverse reactions (<xref rid="TO_LINK" ref-type="bibr" id="IDe2cab56f-acdf-418b-b8eb-8e473e40f4cc">RR 1.30, 95% CI, 0.93-1.83</xref>) with substantial variability between the studies (test for heterogeneity <italic>p </italic>= .08, I<xref ref-type="fn" rid="bibd2e303"/>=39.4%), the risk difference was 9% (<xref rid="TO_LINK" ref-type="bibr" id="IDfae509b8-839d-48a2-9c2a-7505abe07bb5">CI 95% 0-18%</xref>) (<xref rid="TO_LINK" ref-type="bibr" id="IDaed55b20-3036-42ae-836f-afe574ec3f8d">table 4</xref>). </p>
        </sec>
        <sec>
          <title>Discussion</title>
          <p>Our intent was to to determine the quality of evidence and apparent magnitude of impact of prokinetic agents on symptoms, endoscopic healing, and adverse effects in patients with gastroesophageal reflux.  We found an increase in the probability of symptom improvement of 68% with treatment (<xref rid="TO_LINK" ref-type="bibr" id="ID8a1478a6-6e83-4711-8b42-be5eac57b06c">RR 1.68, 95% CI, 1.31-2.17</xref>), and 35% (<xref rid="TO_LINK" ref-type="bibr" id="ID4626dcc5-7c56-44e5-8a96-cebdb05795fb">RR 1.35, 95% CI 1.05-1.72</xref>) in the probability of endoscopic healing or improvement, but we didn&#8217;t find a significant increase on adverse reactions with treatment (<xref rid="TO_LINK" ref-type="bibr" id="IDefeede69-3ee2-4974-9f05-f343cc593ac9">RR 1.30, 95% CI, 0.93-1.83</xref>). The last two outcomes showed substantial variability between the studies. </p>
          <p>The GRADE system of rating quality of evidence provides a structure for assessing the quality of the evidence<xref ref-type="fn" rid="bibd2e326"/>. In the GRADE system, randomized trials constitute high quality evidence unless there are important limitations. The 12 trials addressing symptomatic improvement were of moderate to high quality, results were consistent, confidence intervals reasonably narrow, and the results apply directly to the relevant population (<xref rid="TO_LINK" ref-type="bibr" id="ID0b5e5802-f634-4ec5-9e59-3ead996c2e03">table 5</xref>) .The trials, however, were small, a number were industry funded, and the funnel plot, suggested the possibility of publication bias, a substantial risk when evidence comes from a number of small trials. In our judgment, therefore, we have moderate evidence of symptomatic benefit with prokinetic agents.</p>
          <p>With respect to endoscopic improvement, the 10 relevant randomized trials were of moderate to high quality and provide direct evidence regarding the impact of prokentic agents.  The results, however, were not consistent across studies (test for heterogeneity <italic>p </italic>= .006, I<xref ref-type="fn" rid="bibd2e342"/> 60.7%) (and our a priori hypotheses failed to explain differences in the magnitude of effect across studies), the confidence intervals around the effect wide (<xref rid="TO_LINK" ref-type="bibr" id="ID6811c210-29a1-4fe0-a204-062331def85d">RR 1.35, 95% CI 1.05-1.72</xref>), and the studies concerns about publication bias arise. We therefore conclude that the resulte provide only very weak evidence supporting the benefits of prokinetic agents on endoscopic healing. </p>
          <p>With respect to adverse effects, these randomized trials were of moderate to high quality and the results are directly applicable to the patient population. The results are, however, inconsistent (test for heterogeneity <italic>p </italic>= .08, I<xref ref-type="fn" rid="bibd2e366"/>=39.4%) and the confidence intervals wide (<xref rid="TO_LINK" ref-type="bibr" id="IDa74185e2-c73c-4c0d-b1dd-87e34a6a3d75">RR 1.30, 95% CI, 0.93-1.83</xref>). Results therefore provide weak evidence of toxicity of prokinetic agents.  Furthermore, the studies are extremely underpowered to detect rare but serious side effects.  Case reports of cardiovascular adverse effects remain, therefore, an important concern. 27, 28, 29</p>
          <p>Strengths of our systematic review includes explicit, detailed eligibility criteria; a comprehensive search; restriction to RCTs of moderate or high methodological quality; high levels of agreement on issues requiring judgement; and our use of the systematic GRADE approach to rate the quality of the evidence. Limitations are in the number of patients studied, and the methodological limitations (<xref rid="TO_LINK" ref-type="bibr" id="ID20457c30-cb78-4b75-bc82-5f3e23d202fe">in particular the possibility of publication bias</xref>) that we have highlighted.</p>
          <p>In summary, while patients with GERD are likely to benefit symptomatically from use of prokinetic agents, some uncertainty remains. The magnitude of side effects and toxicity is uncertain. Clinicians must also consider the higher quality evidence available for other agents in making their therapeutic decisions.</p>
        </sec>
      </sec>
      <sec>
        <title>Acknoledgement</title>
        <p>We would like to thank Karin Kirmayr, Lisandro Pereyra, Martin Diaz, Clara Perret and Jose Mella, who provided aid for the translation and final details in the drafting of the manuscript.</p>
      </sec>
      <sec>
        <title>Figure 1 outlines the flow of articles considered for the review.</title>
        <p>49 Excluded </p>
        <table-wrap specific-use="rules" id="ID09cf73a8-dc33-4c5c-be95-14977d12cc63" position="float" orientation="portrait">
          <label>Table 1</label>
          <caption>
            <p>General Characteristics of 17 Included RCTs</p>
          </caption>
          <table>
            <tr>
              <td rowspan="1" colspan="1">Reference (<xref rid="TO_LINK" ref-type="bibr" id="IDafd13314-a2f1-4549-8dfd-46d8583762a3">country</xref>) year</td>
              <td rowspan="1" colspan="1">N&#186; of patients<break/>
                     </td>
              <td rowspan="1" colspan="1">Drug, Dose, Posology</td>
              <td rowspan="1" colspan="1">Concomitant treatment in experimental and control groups</td>
              <td rowspan="1" colspan="1">Treatment duration</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Baldi F et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID50d5a1d8-eb46-499d-bb51-2533e6baea6f">Italy</xref>) 1988 (<xref rid="TO_LINK" ref-type="bibr" id="IDcdb9dd5e-4420-4d26-b8dc-29bf3d7cdb94">5</xref>)</td>
              <td rowspan="1" colspan="1">63</td>
              <td rowspan="1" colspan="1">Cisapride 10mg x 4 </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Collins BJ et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID9dd78211-26b5-426c-b93c-9d77854a4f19">United Kingdom</xref>) 1987 (<xref rid="TO_LINK" ref-type="bibr" id="IDabc4c4cb-af77-487e-9b03-ea63e9d2bd76">6</xref>)</td>
              <td rowspan="1" colspan="1">18</td>
              <td rowspan="1" colspan="1">Cisapride 10mg x 3</td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">4 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Finizia C et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID045cefba-1928-475a-9bbb-789d623657d0">Sweden</xref>) 2002 (<xref rid="TO_LINK" ref-type="bibr" id="ID293aee57-fe67-4813-a5be-6d0ee23199ed">7</xref>)</td>
              <td rowspan="1" colspan="1">30</td>
              <td rowspan="1" colspan="1">Cisapride 20mg x 2</td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">2 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Galmiche JP et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID9df59dd7-5f98-4bbc-bf57-6cba1e40402d">Francia</xref>) 19<xref rid="TO_LINK" ref-type="bibr" id="IDf0188d65-3bbb-4564-bb68-8a3a1a8b86a1">8</xref>8 (8)</td>
              <td rowspan="1" colspan="1">47</td>
              <td rowspan="1" colspan="1">Cisapride 10mg x 4 + Cimetidine</td>
              <td rowspan="1" colspan="1">Cimetidine</td>
              <td rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hatlebakk JG et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID47e25c34-163b-427c-89bb-3207f71ec342">Norway</xref>) 1<xref rid="TO_LINK" ref-type="bibr" id="ID1ecd35db-752f-4107-aed2-7d9c0f2d5c00">9</xref>99 (9)</td>
              <td rowspan="1" colspan="1">107</td>
              <td rowspan="1" colspan="1">Cisapride 20mg x 2</td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">8 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lepoutre L et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID0740324e-6167-4a7e-a1a8-378e4d6e3fa7">Belgium</xref>) 1990 (<xref rid="TO_LINK" ref-type="bibr" id="ID3efae726-fdb5-4a48-88ba-7a95975daf3f">10</xref>)</td>
              <td rowspan="1" colspan="1">20</td>
              <td rowspan="1" colspan="1">Cisapride 10mg x 4 </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">16 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lieberman DA et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDe9dd24bb-9c1a-473e-803b-4bcd5f9434e0">USA</xref>) 1986 (<xref rid="TO_LINK" ref-type="bibr" id="ID6485bb8a-87e9-4f84-b36f-40bc7ff89435">11</xref>)</td>
              <td rowspan="1" colspan="1">25</td>
              <td rowspan="1" colspan="1">Metoclopramide 10mg x 4 + Cimetidine</td>
              <td rowspan="1" colspan="1">Cimetidine</td>
              <td rowspan="1" colspan="1">8 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">McCallum et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID94be603a-98ed-408b-b16d-b635232111e0">USA</xref>) 1984 (<xref rid="TO_LINK" ref-type="bibr" id="ID24443b9e-8a3d-47be-a9d2-e78e4da1d817">13</xref>)</td>
              <td rowspan="1" colspan="1">19</td>
              <td rowspan="1" colspan="1">Metoclopramide 10mg x 4 </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">4 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Mc Kenna CJ et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID826fca33-cccc-42f7-8c1c-fec80e528c07">United Kingdom</xref>) 1995 (<xref rid="TO_LINK" ref-type="bibr" id="ID660c08cf-2018-4224-9b12-aec02838a8c8">14</xref>)</td>
              <td rowspan="1" colspan="1">344</td>
              <td rowspan="1" colspan="1">Cisapride 20mg x2 + Ranitidine</td>
              <td rowspan="1" colspan="1">Ranitidine</td>
              <td rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Masci E et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID27092c33-f7d1-4dd3-9fd6-1037aed05397">Italy</xref>) 1992 (<xref rid="TO_LINK" ref-type="bibr" id="IDd2bf03a2-3486-44fa-9149-9ce4c033bc1d">12</xref>)</td>
              <td rowspan="1" colspan="1">30 *</td>
              <td rowspan="1" colspan="1">Levosulpiride 25mg x3/ Domperidone 10mg x 3</td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Nicolaidis CL et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID1e5988d0-8f60-4f23-8b92-75f9f21a7d5a">Greece</xref>) 1987 (<xref rid="TO_LINK" ref-type="bibr" id="IDa509ecf1-28d6-4fe5-a36e-aaa4117ddd11">15</xref>)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">Cisapride 10mg x 3</td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">4 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Nicolaidis CL et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDae8ab990-7da1-4dc6-a0dd-188e388a0bfd">Greece</xref>) 1987 (<xref rid="TO_LINK" ref-type="bibr" id="IDf813a1a8-7be1-4505-8671-ebcf4b32f9d9">15</xref>)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">Cisapride 5mg x 3</td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">4 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pehlivanov N et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDd3aa8286-70b8-41af-ac72-a3b4dd8b94d2">USA</xref>) 2002 (<xref rid="TO_LINK" ref-type="bibr" id="ID5c620077-bcb6-4461-a7a1-5868f03e426b">16</xref>)</td>
              <td rowspan="1" colspan="1">10</td>
              <td rowspan="1" colspan="1">Cisapride 10mg x 4 </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">5 days</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Richter JE et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID60b27785-f47c-4111-a025-5bd8eb3d2a4a">USA</xref>) 1995 (<xref rid="TO_LINK" ref-type="bibr" id="IDb207c95f-d44e-480a-bd5b-387f56df2939">17</xref>)</td>
              <td rowspan="1" colspan="1">177</td>
              <td rowspan="1" colspan="1">Cisapride 10mg x 4 </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Richter JE et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID933b7eb2-f509-4aa2-9b67-337b9efeb75d">USA</xref>) 1995 (<xref rid="TO_LINK" ref-type="bibr" id="ID00c5fb52-0595-436f-b8b6-73bcba0a635c">17</xref>)</td>
              <td rowspan="1" colspan="1">177</td>
              <td rowspan="1" colspan="1">Cisapride 20mg x 4 </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Robertson CS et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID8da42a10-8dea-469e-99b7-2695eb6ac075">United Kingdom</xref>) 1993 (<xref rid="TO_LINK" ref-type="bibr" id="ID9a0f30c2-7657-4635-8821-5bb63e8667c6">18</xref>)</td>
              <td rowspan="1" colspan="1">46</td>
              <td rowspan="1" colspan="1">Cisapride 10mg x 4 </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Temple JG et al.(<xref rid="TO_LINK" ref-type="bibr" id="IDaf695344-2410-4a18-ba3c-40926cc95d46">United Kingdom</xref>) <xref rid="TO_LINK" ref-type="bibr" id="ID79b2bbaa-e6f6-4b5f-9540-129531cbf652">19</xref>83 (19)</td>
              <td rowspan="1" colspan="1">73</td>
              <td rowspan="1" colspan="1">Metoclopramide 10mg x 3 + Cimetidine</td>
              <td rowspan="1" colspan="1">Cimetidine</td>
              <td rowspan="1" colspan="1">12 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Thanik KD et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDe89f3250-4e21-4a28-9644-bed5df04eb9c">USA</xref>) 1980 (<xref rid="TO_LINK" ref-type="bibr" id="IDc74c7ad8-1c86-4f21-b107-73a586479a5a">20</xref>)</td>
              <td rowspan="1" colspan="1">44</td>
              <td rowspan="1" colspan="1">Bethanechol 25mg x 4</td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">4 weeks</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Trabucchi E et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDfe5f158b-1684-4a5c-80a3-565d93386c0f">Italy</xref>) (<xref rid="TO_LINK" ref-type="bibr" id="ID266a4825-4c0a-4783-9903-10d91006396a">21</xref>)</td>
              <td rowspan="1" colspan="1">30</td>
              <td rowspan="1" colspan="1">L-sulpiride 25 mg x 3</td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">4 weeks</td>
            </tr>
          </table>
        </table-wrap>
        <p>Abbreviations: PD/CT, prokinetic drug/comparison treatment; NA, not available</p>
      </sec>
      <sec>
        <title>* Number of patients enrolled in each arm weren&#8217;t reported.</title>
        <table-wrap specific-use="rules" id="ID2a7baa4d-f014-42e3-bd19-f3bbf1a1057c" position="float" orientation="portrait">
          <label>Table 2</label>
          <caption>
            <p>Quality of RCTs</p>
          </caption>
          <table>
            <tr>
              <td rowspan="1" colspan="1">Reference (<xref rid="TO_LINK" ref-type="bibr" id="IDeb0e4bd1-9001-4d5d-a8db-aad54b079dca">country</xref>) year</td>
              <td rowspan="1" colspan="1">Concealment <break/>allocation</td>
              <td rowspan="1" colspan="1">Blinding</td>
              <td rowspan="1" colspan="1"> Follow-up</td>
              <td rowspan="1" colspan="1">Jadad scale modified by Schulz criteria<break/>(<xref rid="TO_LINK" ref-type="bibr" id="ID5ccb6c67-cc72-412d-bbc6-fddcefbd168c">Score 0-8</xref>)</td>
              <td rowspan="1" colspan="1">Pharmaceutical Industry sponsored</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Baldi F et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDda3d7db9-a428-471d-8fdc-863ea11e0693">Italy</xref>) 1988 (<xref rid="TO_LINK" ref-type="bibr" id="ID73796f9b-69db-4d06-a3f8-fb52c6ff4cbb">5</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">59%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Collins BJ et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDbb62b58c-e06d-4229-bfd7-c8393815c2cd">United Kingdom</xref>) 1987 (<xref rid="TO_LINK" ref-type="bibr" id="IDd3f8e9cb-d1ec-431c-a5c9-12cb87be03cb">6</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients, health care providers and investigators #</td>
              <td rowspan="1" colspan="1">100%</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Finizia C et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDcfc74b46-25ce-4991-b615-03931ded14ea">Sweden</xref>) 2002 (<xref rid="TO_LINK" ref-type="bibr" id="IDaed83737-c0f8-4687-bc38-a2491934f608">7</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">100%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Galmiche JP et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID93cb15ec-c1aa-4298-95b5-249225977153">Francia</xref>) 19<xref rid="TO_LINK" ref-type="bibr" id="ID451650c5-de79-4290-b134-8ec8fa9db0f4">8</xref>8 (8)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">100%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hatlebakk JG et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID4e47e90c-bd9a-4da5-8dc1-7d1844fdb76a">Norway</xref>) 1<xref rid="TO_LINK" ref-type="bibr" id="ID611e996c-f36c-40e4-9660-c28e3887642c">9</xref>99 (9)</td>
              <td rowspan="1" colspan="1">Certain<break/>
                     </td>
              <td rowspan="1" colspan="1">Patients, health care providers and data collectors</td>
              <td rowspan="1" colspan="1">100%</td>
              <td rowspan="1" colspan="1">7</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lepoutre L et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID15a4490d-dad0-478b-8eea-56dee590b160">Belgium</xref>) 1990 (<xref rid="TO_LINK" ref-type="bibr" id="ID754e3eec-4aa3-4049-a399-d51bcfa23f68">10</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">100%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lieberman DA et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID10069927-2215-4e91-976f-e6c87710f054">USA</xref>) 1986 (<xref rid="TO_LINK" ref-type="bibr" id="IDa3aedbf6-db24-4adf-848e-63177d179c89">11</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">96%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">McCallum et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID3262433c-21d3-4276-afc1-29d0020ace4f">USA</xref>) 1984 (<xref rid="TO_LINK" ref-type="bibr" id="ID6e2218c4-c085-4042-b02c-56d3e1195217">13</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">95%</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">NO</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Mc Kenna CJ et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID43005059-8b85-4007-8407-c378ecf09abc">United Kingdom</xref>) 1995 (<xref rid="TO_LINK" ref-type="bibr" id="IDece4c8c6-9760-49b9-a6d2-bf7f10b875bf">14</xref>)</td>
              <td rowspan="1" colspan="1">Probably</td>
              <td rowspan="1" colspan="1">Patients, follow-up endoscopists and investigators #</td>
              <td rowspan="1" colspan="1">92%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">double blind #</td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Nicolaidis CL et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID8d046bfe-5a25-45cd-a753-f54a759414a1">Greece</xref>) 1987 (<xref rid="TO_LINK" ref-type="bibr" id="ID82d4f813-aa23-4517-97cb-72faf8e91ab9">15</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">100%</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pehlivanov N et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID82915b9c-ac68-474d-b09d-468415244ca3">USA</xref>) 2002 (<xref rid="TO_LINK" ref-type="bibr" id="IDae9761ad-2443-451d-942f-db3df7f27704">16</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">100%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Richter JE et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDea4b14d4-4577-451e-91ff-4d34d72c4364">USA</xref>) 1995 (<xref rid="TO_LINK" ref-type="bibr" id="IDbcc4fbc7-c37a-4f89-a49a-60e68a1ec63c">17</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">89%</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Robertson CS et al. (<xref rid="TO_LINK" ref-type="bibr" id="ID71a20358-4908-4c20-a793-f7ebc6e02576">United Kingdom</xref>) 1993 (<xref rid="TO_LINK" ref-type="bibr" id="IDdd6081c3-20f9-4e2d-95a3-5c899d6c077d">18</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">double blind #</td>
              <td rowspan="1" colspan="1">96%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Temple JG et al.(<xref rid="TO_LINK" ref-type="bibr" id="ID18c6acc7-20d1-42cf-bb48-139a8ed4d3e2">United Kingdom</xref>) <xref rid="TO_LINK" ref-type="bibr" id="IDe0166623-c7f1-44f0-b259-5abe0d72c632">19</xref>83 (19)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #<break/> (<xref rid="TO_LINK" ref-type="bibr" id="IDd710b193-c1e1-4b47-9755-80083f5bbf1e">Double dummy technique</xref>)</td>
              <td rowspan="1" colspan="1">96%</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Thanik KD et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDbca296dd-c718-4e3b-8ec3-483cdcdb3169">USA</xref>) 1980 (<xref rid="TO_LINK" ref-type="bibr" id="ID3d7309cf-ed0a-47f9-8161-1dbfcd0afb79">20</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">Patients and investigators #</td>
              <td rowspan="1" colspan="1">100%</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">YES</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Trabucchi E et al. (<xref rid="TO_LINK" ref-type="bibr" id="IDe9794f4d-47cc-42db-9200-5b71dacd60d1">Italy</xref>) (<xref rid="TO_LINK" ref-type="bibr" id="ID0db740d8-5145-4fd5-8a9e-7c1d3708ac7e">21</xref>)</td>
              <td rowspan="1" colspan="1">Definitely not</td>
              <td rowspan="1" colspan="1">double blind #</td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
          </table>
        </table-wrap>
        <sec>
          <title>Masci E et al. (Italy) 1992 (12)</title>
        </sec>
        <sec>
          <title>Definitely not</title>
        </sec>
      </sec>
    </sec>
    <sec>
      <title># Not defined further. </title>
    </sec>
    <sec>
      <title>NA Not available.</title>
      <sec>
        <title/>
        <fig position="float" orientation="portrait">
          <p>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="media/image1.jpeg" id="IDaf52373b-5366-478f-922d-e1cea625bdcd" position="float" orientation="portrait" xlink:type="simple">
              <label>Figure 2</label>
              <caption>
                <p>Meta analysis</p>
              </caption>
            </graphic>
          </p>
        </fig>
        <table-wrap specific-use="rules" id="ID578ab8e8-2fa4-467e-8e0d-e125d366637d" position="float" orientation="portrait">
          <label>Table 5</label>
          <caption>
            <p>Overall Quality of evidence</p>
          </caption>
          <table>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Study quality</td>
              <td rowspan="1" colspan="1">Precision of estimates</td>
              <td rowspan="1" colspan="1">Consistency<break/>of results</td>
              <td rowspan="1" colspan="1">Directness<break/>of results</td>
              <td rowspan="1" colspan="1">Likelihood of reporting bias</td>
              <td rowspan="1" colspan="1">Overall quality of evidence</td>
              <td rowspan="1" colspan="1">Relative risk and 95% CI</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Symptom improvement</td>
              <td rowspan="1" colspan="1">No serious limitations</td>
              <td rowspan="1" colspan="1">Adequate precision</td>
              <td rowspan="1" colspan="1">YES</td>
              <td rowspan="1" colspan="1">YES</td>
              <td rowspan="1" colspan="1">Suggested</td>
              <td rowspan="1" colspan="1">Moderate</td>
              <td rowspan="1" colspan="1">1.68 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDed42e2da-333f-410e-a096-6826dbf26db9">1.31-2.17</xref>) </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Endoscopic <break/>healing</td>
              <td rowspan="1" colspan="1">No serious limitations</td>
              <td rowspan="1" colspan="1">Wide confidence interval</td>
              <td rowspan="1" colspan="1">NO</td>
              <td rowspan="1" colspan="1">YES</td>
              <td rowspan="1" colspan="1">Suggested</td>
              <td rowspan="1" colspan="1">Very low</td>
              <td rowspan="1" colspan="1">1.35 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID13fa2daf-3a91-4d51-abe6-0d215e56043a">1.05-1.72</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Adverse <break/>effects</td>
              <td rowspan="1" colspan="1">No serious limitations</td>
              <td rowspan="1" colspan="1">Wide confidence interval</td>
              <td rowspan="1" colspan="1">NO</td>
              <td rowspan="1" colspan="1">YES</td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">Low</td>
              <td rowspan="1" colspan="1">1.30 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID52c5f238-81af-49ee-b887-718bd45fd798">0.93-1.83</xref>)</td>
            </tr>
          </table>
        </table-wrap>
      </sec>
      <table-wrap specific-use="rules" id="ID9579e9b8-327b-49e3-bede-dbebd0022157" position="float" orientation="portrait">
        <label>Table 3</label>
        <caption>
          <p>Prokinetic Drug Utility</p>
        </caption>
        <table>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>Outcome</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>No. of Studies/ patients</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Treatment Group</bold>
              <break/>
              <bold>n improved/ n total</bold>
              <break/>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Control Group</bold>
              <break/>
              <bold>n improved/ n total</bold>
              <break/>
            </td>
            <td rowspan="1" colspan="1">
              <bold>RR (<xref rid="TO_LINK" ref-type="bibr" id="ID5002fd96-508d-42cc-81b2-fa73d9560a56">CI 95%</xref>) random effect</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Risk Difference (<xref rid="TO_LINK" ref-type="bibr" id="ID8ecc0785-3e47-4fa3-b365-d3cbc3c72b30">CI 95%</xref>) random effect</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>1) Cisapride &lt;40mg/d</bold>
            </td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Clinical improvement</td>
            <td rowspan="1" colspan="1">2/58</td>
            <td rowspan="1" colspan="1">
              <bold>29/37</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>9/21</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>1.77 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID6c79a46c-4947-4cd8-b807-f340c058f49d">1.03-3.04</xref>)</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>34% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID3ba4ffb5-3f0e-440f-abba-13d18a92711c">9-60</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>2) Cisapride &#61619;40mg/d</bold>
            </td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Endoscopic improvement or healing</td>
            <td rowspan="1" colspan="1">3/244</td>
            <td rowspan="1" colspan="1">
              <bold>98/151</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>46/93</bold>
            </td>
            <td rowspan="1" colspan="1"> </td>
            <td rowspan="1" colspan="1">
              <bold>36% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID007f5ab5-6ce0-4f41-962a-1ce602c5e3ad">1-72</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Clinical improvement</td>
            <td rowspan="1" colspan="1">4/220</td>
            <td rowspan="1" colspan="1">
              <bold>52/113</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>33/107</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>1.49 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID5c41b9c7-1c67-4951-8824-a204968a0764">1.13-1.96</xref>)</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>16% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDf87c0023-882d-47a2-9556-4c700af7c5a9">6-27</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>3) Cisapride (<xref rid="TO_LINK" ref-type="bibr" id="IDff088395-4ddf-4491-8c58-966381dabda1">any doses</xref>)</bold>
            </td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Endoscopic improvement or healing</td>
            <td rowspan="1" colspan="1"> 6/757</td>
            <td rowspan="1" colspan="1">
              <bold>254/378</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>200/379</bold>
            </td>
            <td rowspan="1" colspan="1"> </td>
            <td rowspan="1" colspan="1">
              <bold>26% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID0dee0d9b-6ad4-4d5f-b8c7-0288782d7e2b">10-41</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Clinical improvement</td>
            <td rowspan="1" colspan="1">6/278</td>
            <td rowspan="1" colspan="1">
              <bold>81/150</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>42/128</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>1.54 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID01b44c33-d0ef-48a5-8e12-02b018b214bf">1.21-2.11</xref>)</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>19% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID309d744a-2ccd-4a0f-a0c5-441075c41d8a">9-29</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>4) Metoclopramide 30mg/d</bold>
            </td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Endoscopic improvement or healing </td>
            <td rowspan="1" colspan="1">1/73</td>
            <td rowspan="1" colspan="1">8/33</td>
            <td rowspan="1" colspan="1">18/40</td>
            <td rowspan="1" colspan="1">0.54 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDa6149089-21b0-4b0c-ab67-c175c30e31a8">0.27-1.08</xref>)</td>
            <td rowspan="1" colspan="1">-21% (<xref rid="TO_LINK" ref-type="bibr" id="ID6d806c59-38e4-4d12-85ac-0784b1057b1e">-42-0</xref>)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>5) Metoclopramide 40mg/d</bold>
            </td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <disp-quote>
                <p>Endoscopic improvement or healing</p>
              </disp-quote>
            </td>
            <td rowspan="1" colspan="1">2/45</td>
            <td rowspan="1" colspan="1">15/24</td>
            <td rowspan="1" colspan="1">10/21</td>
            <td rowspan="1" colspan="1">1.26 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID1c962e26-2b3a-4598-b787-6ed4bbd25e66">0.5-3.19</xref>)</td>
            <td rowspan="1" colspan="1">13% (<xref rid="TO_LINK" ref-type="bibr" id="ID038a28c1-59a0-4654-8b6a-22b2847ed781">-34-60</xref>)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Clinical improvement </td>
            <td rowspan="1" colspan="1">1/22</td>
            <td rowspan="1" colspan="1">9/13</td>
            <td rowspan="1" colspan="1">2/9</td>
            <td rowspan="1" colspan="1">3.12 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID7c1bd3d4-6e2e-4a12-bd51-b7a6481edab5">0.87-11.15</xref>) </td>
            <td rowspan="1" colspan="1">
              <bold>47% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDd468ef40-bfc5-4d35-ae53-e7692095b8b3">10-84</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>6) Metoclopramide (<xref rid="TO_LINK" ref-type="bibr" id="IDe06a8a48-2360-4f03-9038-eb3fcc81faac">any doses</xref>)</bold>
            </td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Endoscopic improvement or healing </td>
            <td rowspan="1" colspan="1">3/118</td>
            <td rowspan="1" colspan="1">23/57</td>
            <td rowspan="1" colspan="1">28/61</td>
            <td rowspan="1" colspan="1">0.93 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID9686fb11-ea5e-45b7-b69f-d860fd7a5439">0.45-1.94</xref>)</td>
            <td rowspan="1" colspan="1">-1% (<xref rid="TO_LINK" ref-type="bibr" id="ID7049e1bc-acd2-4a7a-9cf2-b32acf152cb1">-36-35</xref>)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Clinical improvement </td>
            <td rowspan="1" colspan="1">1/22</td>
            <td rowspan="1" colspan="1">9/13</td>
            <td rowspan="1" colspan="1">2/9</td>
            <td rowspan="1" colspan="1">3.12 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID85875a8c-6886-4fef-8c82-e0d4dd350e4f">0.87-11.15</xref>) </td>
            <td rowspan="1" colspan="1">
              <bold>47% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDd6520397-6501-4202-8c42-3ef793039496">10-84</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>7) Bethanechol 100mg/d</bold>
            </td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Endoscopic improvement or healing</td>
            <td rowspan="1" colspan="1">1/44</td>
            <td rowspan="1" colspan="1">14/22</td>
            <td rowspan="1" colspan="1">8/22</td>
            <td rowspan="1" colspan="1">1.75 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID9dac2d3e-93e0-4cb7-b212-99342520cf7a">0.93-3.31</xref>)</td>
            <td rowspan="1" colspan="1">27% (<xref rid="TO_LINK" ref-type="bibr" id="ID00d0746d-4eda-4919-af67-0c21ac7a0976">-1-56</xref>)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Clinical improvement</td>
            <td rowspan="1" colspan="1">1/44</td>
            <td rowspan="1" colspan="1">
              <bold>10/22</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>3/22</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>3.67 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDaccf637c-ffb9-4959-b4a1-34d614d3df57">1.18-11.37</xref>)</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>36% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDe39f8b41-0f05-40f2-9d67-efdaeb4324ce">11-62</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>8) All prokinetics</bold>
            </td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Endoscopic improvement or healing</td>
            <td rowspan="1" colspan="1"> 10/859</td>
            <td rowspan="1" colspan="1">
              <bold>291/457</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>207/402</bold>
            </td>
            <td rowspan="1" colspan="1"> </td>
            <td rowspan="1" colspan="1">
              <bold>20% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID89f62d78-6c55-4f4b-aa11-6a83a32f5a94">6-34</xref>)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Clinical improvement</td>
            <td rowspan="1" colspan="1">8/347</td>
            <td rowspan="1" colspan="1">
              <bold>101/185</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>47/162</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>1.68 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDf6729100-e9bf-4675-a9d7-363bf7dfcf9d">1.31-2.17</xref>)</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>27% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID2ac5a819-4946-4656-b1ee-c63b42eb79e7">16-38</xref>)</bold>
            </td>
          </tr>
        </table>
      </table-wrap>
      <table-wrap specific-use="rules" id="ID3f532bf4-5583-4e26-8a25-383df9d6add4" position="float" orientation="portrait">
        <label>Table 4</label>
        <caption>
          <p>Adverse effects</p>
        </caption>
        <table>
          <tr>
            <td rowspan="1" colspan="1">Adverse effects</td>
            <td rowspan="1" colspan="1">Intervention</td>
            <td rowspan="1" colspan="1">
              <bold>RR (<xref rid="TO_LINK" ref-type="bibr" id="ID204be99e-359e-4887-a672-ea2e30702b29">CI 95%</xref>) random effect</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Risk Difference (<xref rid="TO_LINK" ref-type="bibr" id="ID8e310d30-8aba-4618-b1e7-a2bff2c70b38">CI 95%</xref>) random effect</bold>
            </td>
            <td rowspan="1" colspan="1">No. of studies</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">General AE</td>
            <td rowspan="1" colspan="1">Any prokinetic and dose</td>
            <td rowspan="1" colspan="1">1,30 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDe59a1eed-9f3b-490a-842d-414932ed1f82">0,93-1,83</xref>)</td>
            <td rowspan="1" colspan="1">9% (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID5ce6639e-dd54-4e12-9463-df8f3d08e90a">0-18</xref>)</td>
            <td rowspan="1" colspan="1">12</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Gastrointestinal (<xref rid="TO_LINK" ref-type="bibr" id="IDf8f41393-f216-44dd-ac84-718605c5c6a2">any</xref>)</td>
            <td rowspan="1" colspan="1">Any prokinetic and dose</td>
            <td rowspan="1" colspan="1">1,09 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID3a94c0e2-7215-4ae8-a900-d2d9f3a81b05">0,66-1,79</xref>)</td>
            <td rowspan="1" colspan="1">0% (<xref rid="TO_LINK" ref-type="bibr" id="IDc0a999ac-2329-485d-84ca-61ce654045dd">-5-5</xref>)</td>
            <td rowspan="1" colspan="1">8</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Neurological (<xref rid="TO_LINK" ref-type="bibr" id="IDdaa20c01-c118-4ea5-b56d-c98bb444e46c">any</xref>)</td>
            <td rowspan="1" colspan="1">Any prokinetic and dose</td>
            <td rowspan="1" colspan="1">1,03 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDae8b1160-be38-43ef-9d48-fd05349f19f4">0,58-1,84</xref>)</td>
            <td rowspan="1" colspan="1">0.04% (<xref rid="TO_LINK" ref-type="bibr" id="ID43d4b45e-efbd-451a-93b0-5ca63b0fa5e3">-0.04-0.12</xref>)</td>
            <td rowspan="1" colspan="1">9</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Gastrointestinal (<xref rid="TO_LINK" ref-type="bibr" id="ID1a7c8029-413c-48cc-be45-89303769c99b">any</xref>)</td>
            <td rowspan="1" colspan="1">Cisapride (<xref rid="TO_LINK" ref-type="bibr" id="ID8e80303c-ddc7-4498-897d-d2879f3cc20c">any dose</xref>)</td>
            <td rowspan="1" colspan="1">1,05 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDdd1f6c8c-1e98-4b07-914a-a0ed8251e7b1">0,64-1,74</xref>)</td>
            <td rowspan="1" colspan="1">0% (<xref rid="TO_LINK" ref-type="bibr" id="ID1a71e8e2-8034-48da-9a06-c778d64161c1">-0.07-0.06</xref>)</td>
            <td rowspan="1" colspan="1">7</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Neurological (<xref rid="TO_LINK" ref-type="bibr" id="ID24bc32cf-d7ab-4f36-8a89-98bc992df171">any</xref>)</td>
            <td rowspan="1" colspan="1">Cisapride (<xref rid="TO_LINK" ref-type="bibr" id="IDd8cc62e6-b562-4434-907b-140e584d5811">any dose</xref>)</td>
            <td rowspan="1" colspan="1">0,61 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID6700f094-153c-4f71-a1de-b8f79e75bbf3">0,32-1,15</xref>)</td>
            <td rowspan="1" colspan="1">-0.02% (<xref rid="TO_LINK" ref-type="bibr" id="IDfed4dd04-f164-428d-bff1-3a8622f5b889">-0.09-0.05</xref>)</td>
            <td rowspan="1" colspan="1">6</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Headache</td>
            <td rowspan="1" colspan="1">Cisapride &gt; 40mg/d</td>
            <td rowspan="1" colspan="1">0,65 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDc0f63465-8645-4947-b2b8-4eedaed6f0ec">0,33-1,28</xref>)</td>
            <td rowspan="1" colspan="1">0% (<xref rid="TO_LINK" ref-type="bibr" id="ID87e0c56e-26c4-437b-9fd5-ca9048daba14">-0.08-0.08</xref>)</td>
            <td rowspan="1" colspan="1">4</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Diarrhea</td>
            <td rowspan="1" colspan="1">Cisapride &gt; 40mg/d</td>
            <td rowspan="1" colspan="1">0,99 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="ID3aa2366e-1b10-4fd2-8419-4d0a6d5a67d1">0,47-2,09</xref>)</td>
            <td rowspan="1" colspan="1">-0.01% (<xref rid="TO_LINK" ref-type="bibr" id="ID74f32bee-c0f8-4c29-9334-f034657d9133">-0.09-0.07</xref>)</td>
            <td rowspan="1" colspan="1">3</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Neurological (<xref rid="TO_LINK" ref-type="bibr" id="ID0ec5602a-3dc5-4ded-b96f-41801936bfd4">any</xref>)</td>
            <td rowspan="1" colspan="1">Metoclopramide (<xref rid="TO_LINK" ref-type="bibr" id="ID965c0da0-8628-40af-b8b0-c2a10afbac39">any dose</xref>)</td>
            <td rowspan="1" colspan="1">2.41 (<xref rid="IDeb8528a4-d517-488c-a621-f4c30512d8db" ref-type="bibr" id="IDd7d94a44-18b3-487c-ad6c-ad4630a9643e">1.25-4.64</xref>)</td>
            <td rowspan="1" colspan="1">34% (<xref rid="TO_LINK" ref-type="bibr" id="ID4922abe7-f429-4962-8b29-d57bc7e026e0">-16-83</xref>)</td>
            <td rowspan="1" colspan="1">2</td>
          </tr>
        </table>
      </table-wrap>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="bibd2e66">
        <p>Pehlivanov N, Sarosiek I, Whitman R, Olyaee M, McCallum R. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2002 Apr;16(4):743-7. </p>
      </fn>
      <fn id="bibd2e75">
        <p>Nicolaidis CL, Kehagiolou K, Mantzanaris G, Papadatou-Marinou A, Saklaridis J, Georgiotis D, Michailidis D. Therapeutic effect of two dosages of cisapride in controlling chronic reflux symptoms in esophagitis patients. Current Therapeutic Researh, Clinical &amp; Experimental. 42 (6):1059-65, 1987. </p>
      </fn>
      <fn id="bibd2e95">
        <p>McKenna CJ, Mills JG, Goodwin C, Wood JR. Combination of ranitidine and cisapride in the treatment of reflux oesophagitis. Eur J Gastroenterol Hepatol. 1995 Sep;7(9):817-22. </p>
      </fn>
      <fn id="bibd2e99">
        <p>McCallum RW, Fink SM, Winnan GR, Avella J, Callachan C. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. Am J Gastroenterol. 1984 Mar;79(3):165-72. </p>
      </fn>
      <fn id="bibd2e107">
        <p>Masci E, Sorghi M, Tosi T, Testoni PA, Tottobello A. Levosulpiride and domperidone in the treatment of reflux esophagitis: results of a double-blind study versus placebo. Current Therapeutic Researh, Clinical &amp; Experimental. 51(6):814-18, 1992. </p>
      </fn>
      <fn id="bibd2e113">
        <p>Lieberman DA, Keeffe EB. Treatment of severe reflux esophagitis with cimetidine and metoclopramide. Ann Intern Med. 1986 Jan;104(1):21-6. </p>
      </fn>
      <fn id="bibd2e147">
        <p>Lepoutre L, Van der Spek P, Vanderlinden I, Bollen J, Laukens P. Healing of grade-II and III oesophagitis through motility stimulation with cisapride. Digestion. 1990;45(2):109-14. </p>
      </fn>
      <fn id="bibd2e165">
        <p>Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schulz T, Mowinckel P, Bernklev T, Berstad A. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ. 1999 Aug 28;319(7209):550-3. </p>
      </fn>
      <fn id="bibd2e180">
        <p>Galmiche JP, Brandstatter G, Evreux M, Hentschel E, Kerstan E, Kratochvil P, Reichel W, Schutze K, Soule JC, Vitaux J. Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut. 1988 May;29(5):675-81. </p>
      </fn>
      <fn id="bibd2e194">
        <p>Finizia C, Lundell L, Cange L, Ruth M. The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2002 Jan;14(1):9-14. </p>
      </fn>
      <fn id="bibd2e231">
        <p>Collins BJ, Spence RA, Ferguson R, Laird J, Love AH. Cisapride: influence on oesophageal and gastric emptying and gastro-oesophageal reflux in patients with reflux oesophagitis. Hepatogastroenterology. 1987 Jun;34(3):113-6. </p>
      </fn>
      <fn id="bibd2e240">
        <p>Baldi F. Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial. J Clin Gastroenterol. 1988 Dec;10(6):614.</p>
      </fn>
      <fn id="bibd2e249">
        <p>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.</p>
      </fn>
      <fn id="bibd2e258">
        <p>Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, et al. Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses. Health Technology Assessment 1999; 3(12). </p>
      </fn>
      <fn id="bibd2e274">
        <p>Augood C, MacLennan S, Gilbert R, Logan S. Cisapride treatment for gastro-oesophageal reflux in children. In: The Cochrane Library, Issue 2, 2005. Oxford: Update Sofware.</p>
      </fn>
      <fn id="bibd2e287">
        <p>van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. In: The Cochrane Library, Issue 2, 2005. Oxford: Update Sofware. </p>
      </fn>
      <fn id="bibd2e303">
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_Abstract&amp;term=&quot;Ottenjann+R&quot;%5BAuthor%5D" ext-link-type="uri" xlink:type="simple">Ottenjann R</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_Abstract&amp;term=&quot;Seib+HJ&quot;%5BAuthor%5D" ext-link-type="uri" xlink:type="simple">Seib HJ</ext-link>. Endoscopic biopsy study for staging of reflux esophagitis. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="javascript:AL_get(this, 'jour', 'Z Gastroenterol.');" ext-link-type="uri" xlink:type="simple">Z Gastroenterol.</ext-link> 1991 Jul;29(7):360-2.</p>
      </fn>
      <fn id="bibd2e326">
        <p>J Dent, J Brun, A M Fendrick, M B Fennerty, J Janssens, P J Kahrilas, K Lauritsen, JC Reynolds, M Shaw and N J Talley. An evidence-based appraisal of reflux disease management--the Genval Workshop Report. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="javascript:AL_get(this, 'jour', 'Gut.');" ext-link-type="uri" xlink:type="simple">Gut.</ext-link> 1999 Apr;44 Suppl 2:S1-16.</p>
      </fn>
      <fn id="bibd2e342">
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_Abstract&amp;term=&quot;Bytzer+P&quot;%5BAuthor%5D" ext-link-type="uri" xlink:type="simple">Bytzer P</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_Abstract&amp;term=&quot;Havelund+T&quot;%5BAuthor%5D" ext-link-type="uri" xlink:type="simple">Havelund T</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_Abstract&amp;term=&quot;Hansen+JM&quot;%5BAuthor%5D" ext-link-type="uri" xlink:type="simple">Hansen JM</ext-link>.Interobserver variation in the endoscopic diagnosis of reflux esophagitis. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="javascript:AL_get(this, 'jour', 'Scand J Gastroenterol.');" ext-link-type="uri" xlink:type="simple">Scand J Gastroenterol.</ext-link> 1993 Feb;28(2):119-25.</p>
      </fn>
      <fn id="bibd2e366">
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="file:///entrez/query.fcgi%3Fcmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15654800&amp;query_hl=1&amp;itool=pubmed_docsum" ext-link-type="uri" xlink:type="simple">DeVault KR, Castell DO; </ext-link> Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005 Jan;100(1):190-200. </p>
      </fn>
    </fn-group>
    <ref-list>
      <ref>
        <mixed-citation>Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. Am J Gastroenterol. 1995 Mar;90(3):423-30. </mixed-citation>
      </ref>
      <ref>
        <mixed-citation>Robertson CS, Evans DF, Ledingham SJ, Atkinson M. Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993 Apr;7(2):181-90. </mixed-citation>
      </ref>
      <ref id="ID49032543-8075-4bbb-aff5-df7df9fd578c">
        <mixed-citation>Temple JG, Bradby GV, O'Connor FO, Panesar KS, Mulligan TO, Robinson TJ, Ward DW. Cimetidine and metoclopramide in oesophageal reflux disease. Br Med J (Clin Res Ed). 1983 Jun 11;286(6381):1863-4. </mixed-citation>
      </ref>
      <ref>
        <mixed-citation>Thanik KD, Chey WY, Shah AN, Gutierrez JG. Reflux esophagitis: effect of oral bethanechol on symptoms and endoscopic findings. Ann Intern Med. 1980 Dec;93(6):805-8. </mixed-citation>
      </ref>
      <ref id="ID680e095f-977c-404f-bdcc-94231f721c94">
        <mixed-citation>Trabucchi E, Radaelli E, Castoldi L, Abelli P, Brambilla A, Fichera G, Diamantini S, Pace M, Foschi D. The effects of L-sulpiride on reflux oesophagitis. Drugs Exp Clin Res. 1991;17(6):317-21. </mixed-citation>
      </ref>
      <ref id="ID93389629-3688-4b8b-988c-389728b2ebad">
        <mixed-citation>Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B.  Grading strength of recommendations and quality of evidence in clinical guidelines:  report from an American College of Chest Physicians task force.  <italic>Chest</italic> 2006; 129(1):174-181.</mixed-citation>
      </ref>
      <ref id="IDe6b3281e-ad66-4fc5-86d9-633255fcf366">
        <mixed-citation>Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. <italic>N Engl J Med.</italic> 1996;335:290-291.</mixed-citation>
      </ref>
      <ref id="IDeb8528a4-d517-488c-a621-f4c30512d8db">
        <mixed-citation>Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. <italic>Ann Pharmacother.</italic> 1999;33:22-26.</mixed-citation>
      </ref>
      <ref>
        <mixed-citation>Vitola J, Vukamovic J, Roden DM. Cisapride-induced torsades de pointes. <italic>J Cardiovasc Electrophysiol.</italic> 1998;9:1109-1113.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
